IMAX on pace for a record year at the box office and analysts expect next year is going to be even better. The move has been driven by high-profile releases like F1 sinners and the latest Mission Impossible. And this month we get Superman and the Fantastic 4.IMAX shares are up over 50% in the past year. Joining us now is Richard Gelfund, IMAX CEO. Rich, it's great to have you on.Uh, and let's start right there. Box office is booming. What's driving it.Um, let's start with the simplest thing, Morgan. really ...

Core Viewpoint - Gold'n Futures Mineral Corp. has completed a strategic corporate restructuring involving the acquisition of six British Columbia companies and the assignment of non-core mineral claims in Newfoundland and Labrador, aimed at strengthening its asset base and simplifying its capital structure [1][4]. Acquisition Details - The company acquired all issued and outstanding shares of six British Columbia-incorporated companies, which own mineral claims in south-central British Columbia, resulting in Gold'n Futures holding 100% legal and beneficial interests in these claims [2][3]. - The acquired BC Claims are located in a key area of British Columbia's copper-porphyry belt, near Rock-Creek Canyon and the Eagle Plains rare-earth extension zone, with potential for copper-gold and rare-earth mineralization [3]. Debt Elimination - In a concurrent transaction, the company assigned the Brady Claims in Newfoundland and Labrador to a director, Stephen Wilkinson, in exchange for the release of $220,537.59 in outstanding shareholder loans and other indebtedness, significantly improving the company's balance sheet [4]. Board Approval - The Board of Directors unanimously approved both the acquisition and the assignment transactions, with no finder's fees involved and no change of control of the company resulting from these transactions [5].

Core Perspective - Sona Nanotech Inc has initiated its first-in-human clinical trial for its THT therapy aimed at late-stage melanoma patients, marking a significant transition from preclinical to clinical testing [1][2][6] Company Developments - The first patient has been dosed in Santiago, Chile, which is a critical milestone for the company [2][3] - The therapy is classified as a device rather than a drug, designed to enhance tumor visibility to the immune system, potentially leading to tumor shrinkage and improved survival rates [2][4] Clinical Trial Details - The clinical trial will begin with an early feasibility study to assess safety, tolerability, and practical usage of the device, alongside efficacy data [4] - The protocol includes patient check-ins on days 1, 7, 14, 21, and 28, with initial results expected by the end of summer [5] Patient Impact - The therapy aims to help patients who have exhausted other treatment options, focusing on making tumors recognizable to the immune system for potential elimination [6]

Core Viewpoint - The FDA issued a Complete Response Letter (CRL) for Ultragenyx's Biologics License Application (BLA) for UX111, a gene therapy for Sanfilippo syndrome type A, citing specific chemistry, manufacturing, and controls (CMC) observations that are resolvable [1][2] Group 1: Company Overview - Ultragenyx Pharmaceutical Inc. is focused on developing therapies for rare and ultra-rare genetic diseases, with a diverse portfolio aimed at addressing high unmet medical needs [6] - The company is led by a management team experienced in rare disease therapeutics, emphasizing time- and cost-efficient drug development [7] Group 2: Product Information - UX111 is an in vivo gene therapy in Phase 1/2/3 development for Sanfilippo syndrome type A (MPS IIIA), a rare fatal lysosomal storage disease with no approved treatment [4] - The therapy targets the SGSH enzyme deficiency, which leads to the accumulation of heparan sulfate in the brain, causing neurodegeneration [4] - UX111 is administered via a one-time intravenous infusion using a self-complementary AAV9 vector to deliver a functional copy of the SGSH gene [4] Group 3: Regulatory Status - The FDA's CRL did not raise any issues regarding the clinical data package or clinical inspections, acknowledging the robustness of the neurodevelopmental outcome data and supportive biomarker data [3] - The company plans to address the CMC observations and resubmit the BLA, anticipating a review period of up to 6 months post-resubmission [2][3] Group 4: Disease Context - Sanfilippo syndrome type A (MPS IIIA) affects approximately 3,000 to 5,000 patients in commercially accessible areas, characterized by rapid neurodegeneration and a median life expectancy of 15 years [5] - The disease is caused by biallelic pathogenic variants in the SGSH gene, leading to a deficiency in the sulfamidase enzyme [5]

LAFAYETTE, Ind., July 11, 2025 (GLOBE NEWSWIRE) -- Wabash (NYSE: WNC) today announced that it will webcast its quarterly earnings conference call to review and discuss its financial results for the second quarter 2025 on Friday, July 25, 2025, beginning at 12:00 p.m. ET. The call and an accompanying slide presentation will be accessible on the "Investors" section of Wabash’s website, www.onewabash.com, under "Events & Presentations." The conference call will be accessible by dialing (800) 715-9871, conferen ...

ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 11, 2025, Capricor announced that it had received a Complete Response Letter (“CRL”) from the FDA regarding its Biologics License Application (“BLA”) for Deramiocel. Following this news, the price of the Company’s stock dropped.  If you purchased Capricor stock and suffered a loss on that investment, y ...

Key Takeaways Investors can construct a portfolio that allows them to get paid monthly. Dividends provide a nice buffer against the impact of drawdowns in other positions. KO, CAT, and MCD would provide the necessary blend needed for monthly income. While most stocks pay quarterly dividends, investors can still construct a portfolio that allows them to get paid monthly.For example, the first stock pays dividends in January, April, July, and October. The second stock pays out in February, May, August, and ...

The Best Outdoor Security Cameras To Keep Watch At All Timeshttps://t.co/RWu0DwK4C5 https://t.co/DUfZlgYHgE ...

Core Viewpoint - PNC Financial Services Group, Inc. is expected to report improved revenues and earnings for Q2 2025, driven by higher net interest income and fee income, despite rising expenses and provisions for credit losses [1][11][18]. Financial Performance Expectations - The earnings surprise history of PNC is strong, with an average surprise of 8.39% over the last four quarters [2]. - The Zacks Consensus Estimate for Q2 earnings per share is $3.56, reflecting a year-over-year increase of 7.9% [18]. - Total revenues are projected at $5.62 billion, indicating a 3.8% year-over-year increase [18]. Net Interest Income (NII) - NII is expected to rise by 1-2% in Q2 2025, supported by stable funding and deposit costs [3][4][11]. - The Zacks Consensus Estimate for NII is $3.55 billion, representing a sequential increase of 2% [5]. Loan Growth - Average loans are anticipated to increase by 1% sequentially, with projections indicating a 1.4% rise [4][5]. - Demand for commercial, industrial, real estate, and consumer loans has remained solid [4]. Non-Interest Revenues - Mortgage revenues are expected to decline by 2.7% sequentially, with estimates at $130.4 million due to stable mortgage rates [6][7]. - Asset management and brokerage income is projected to see a slight decline, with the consensus estimate at $387.8 million [8][10]. - Card and cash management revenues are expected to rise by 4.9% sequentially, with estimates at $726.4 million [12]. Expenses and Asset Quality - Non-interest expenses are projected to be stable at $3.43 billion, despite ongoing investments in technology and digitalization [13][14]. - Provisions for credit losses are expected to increase to $252.5 million, a sequential rise of 15.3% [15]. - Non-performing assets (NPAs) are estimated at $2.38 billion, indicating a 2.2% increase from the previous quarter [16]. Market Conditions - Global M&A activity has improved, with deal-making resuming towards the end of the quarter despite initial market volatility due to tariff announcements [9].

Analysts on Wall Street project that Monarch Casino (MCRI) will announce quarterly earnings of $1.22 per share in its forthcoming report, representing an increase of 2.5% year over year. Revenues are projected to reach $130.37 million, increasing 1.7% from the same quarter last year.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Ahead ...